Sugi Predict

Sugi Predict / Compounds / SCHEMBL876699

SCHEMBL876699

SCHEMBL876699

CN1C(=O)N[C@H](Cc2c[nH]c3ccccc23)C1=O

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 5/20 0.79
▸ MAPT P10636 3/20 0.79
▸ SMN1; SMN2 Q16637 2/20 0.79
▸ IDO1 P14902 2/20 0.79
▸ TP53 P04637 1/20 0.79
▸ GLA P06280 1/20 0.79
▸ CYP3A4 P08684 1/20 0.79
▸ THRB P10828 1/20 0.79
▸ HSD17B10 Q99714 1/20 0.79
▸ KMT2A Q03164 5/20 0.69
▸ POLB P06746 2/20 0.69
▸ KDM4E B2RXH2 1/20 0.69
▸ ALDH1A1 P00352 1/20 0.69
▸ HPGD P15428 1/20 0.69
▸ MEN1 O00255 3/20 0.67
▸ L3MBTL1 Q9Y468 2/20 0.67
▸ LMNA P02545 2/20 0.62
▸ PKM P14618 1/20 0.62
▸ TNF P01375 1/20 0.61
▸ NPSR1 Q6W5P4 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL837717 1.00 RIPK1 (0.79) RIPK1MAPTSMN1; SMN2IDO1TP53
SCHEMBL29764703 1.00 RIPK1 (0.79) RIPK1MAPTSMN1; SMN2IDO1TP53
SCHEMBL877381 1.00 RIPK1 (0.79) RIPK1MAPTSMN1; SMN2IDO1TP53
SCHEMBL14982035 0.89 RIPK1 (0.75) RIPK1MAPTSMN1; SMN2IDO1TP53
SCHEMBL14982036 0.89 RIPK1 (0.75) RIPK1MAPTSMN1; SMN2IDO1TP53
Necrostatin SCHEMBL2030647 0.88 RIPK1 (1.00) RIPK1MAPTSMN1; SMN2IDO1TP53
SCHEMBL7601366 0.88 RIPK1 (0.73) RIPK1MAPTSMN1; SMN2IDO1TP53
Necrostatin SCHEMBL14473477 0.88 RIPK1 (1.00) RIPK1MAPTSMN1; SMN2IDO1TP53
Necrostatin SCHEMBL29351522 0.88 RIPK1 (1.00) RIPK1MAPTSMN1; SMN2IDO1TP53
Necrostatin SCHEMBL856922 0.88 RIPK1 (1.00) RIPK1MAPTSMN1; SMN2IDO1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10799552-B2 Methods for treating diabetic neurotherapy MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2020-10-13 — — US disclosed
EP-2560629-B1 METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS MASSACHUSETTS EYE & EAR INFIRMARY (US) 2020-06-03 — — EP disclosed
US-10639345-B2 Compositions for preserving photoreceptor cells, retinal pigment epithelial cells, or visual function MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2020-05-05 — — US disclosed
US-10617735-B2 Methods and compositions for preserving retinal ganglion cells MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2020-04-14 — — US disclosed
US-20190216881-A1 METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS MASSACHUSETTS EYE AND EAR INFIRMARY 2019-07-18 — — US disclosed
US-20190117724-A1 METHODS FOR TREATING SPINAL CORD INJURY CHILDREN'S MEDICAL CENTER CORPORATION 2019-04-25 — — US disclosed
US-20190099467-A1 METHODS AND COMPOSITIONS FOR PRESERVING RETINAL GANGLION CELLS MASSACHUSETTS EYE AND EAR INFIRMARY 2019-04-04 — — US disclosed
US-20190023690-A1 INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) 2019-01-24 — — US disclosed
US-10022419-B2 Methods for treating spinal cord injury MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2018-07-17 — — US disclosed
US-9993517-B2 Methods and compositions for preserving retinal ganglion cells MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2018-06-12 — — US disclosed
US-20140357570-A1 COMPOSITIONS COMPRISING NECROSIS INHIBITORS, SUCH AS NECROSTATINS, ALONE OR IN COMBINATION, FOR PROMOTING AXON REGENERATION AND NERVE FUNCTION, THEREBY TREATING CNS DISORDERS MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2014-12-04 — — US disclosed
US-20140024598-A1 METHODS AND COMPOSITIONS FOR PRESERVING RETINAL GANGLION CELLS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-01-23 — — US disclosed
US-20130137642-A1 METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-05-30 — — US disclosed
WO-2013059791-A2 METHODS AND COMPOSITIONS FOR PROMOTING AXON REGENERATION AND NERVE FUNCTION MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2013-04-25 — — WO disclosed
US-20120149702-A1 INHIBITORS OF CELLULAR NECROSIS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-06-14 — — US disclosed
WO-2012061045-A2 METHODS AND COMPOSITIONS FOR PRESERVING RETINAL GANGLION CELLS MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2012-05-10 — — WO disclosed
US-8143300-B2 Inhibitors of cellular necrosis PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-03-27 — — US disclosed
WO-2011133964-A2 METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2011-10-27 — — WO disclosed
US-20110144169-A1 Inhibitors of cellular necrosis NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-06-16 — — US disclosed
US-7491743-B2 Inhibitors of cellular necrosis PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2009-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190099467-A1 METHODS AND COMPOSITIONS FOR PRESERVING RETINAL GANGLION CELLS GAP43, PDE6C, NGF RIPK1 410/4885MAPT 888/4885SMN1; SMN2 484/4885
US-20140357570-A1 COMPOSITIONS COMPRISING NECROSIS INHIBITORS, SUCH AS NECROSTATINS, ALONE OR IN COMBINATION, FOR PROMOTING AXON REGENERATION AND NERVE FUNCTION, THEREBY TREATING CNS DISORDERS NGF, NTRK2, BDNF RIPK1 43/4885MAPT 316/4885SMN1; SMN2 7/4885
US-10022419-B2 Methods for treating spinal cord injury NGF, GAP43, BDNF RIPK1 782/4885MAPT 412/4885SMN1; SMN2 7/4885
US-20190216881-A1 METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS ALDH1A2, PDE6B, PDE6C RIPK1 166/4885MAPT 1875/4885SMN1; SMN2 362/4885
US-20140024598-A1 METHODS AND COMPOSITIONS FOR PRESERVING RETINAL GANGLION CELLS GAP43, PDE6C, NGF RIPK1 410/4885MAPT 888/4885SMN1; SMN2 484/4885
US-20190117724-A1 METHODS FOR TREATING SPINAL CORD INJURY NGF, GAP43, BDNF RIPK1 782/4885MAPT 412/4885SMN1; SMN2 7/4885
US-20110144169-A1 Inhibitors of cellular necrosis TNF, AIFM1, BAD RIPK1 135/4885MAPT 831/4885SMN1; SMN2 80/4885
US-20120149702-A1 INHIBITORS OF CELLULAR NECROSIS TNF, AIFM1, BAD RIPK1 135/4885MAPT 831/4885SMN1; SMN2 80/4885
US-20130137642-A1 METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS ALDH1A2, PDE6B, PDE6C RIPK1 166/4885MAPT 1875/4885SMN1; SMN2 362/4885
US-10799552-B2 Methods for treating diabetic neurotherapy NGF, NTRK2, BDNF RIPK1 1105/4885MAPT 351/4885SMN1; SMN2 12/4885
US-20190023690-A1 INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS LITAF, TNF, MMP8 RIPK1 198/4885MAPT 94/4885SMN1; SMN2 665/4885
US-10617735-B2 Methods and compositions for preserving retinal ganglion cells GAP43, PDE6C, NGF RIPK1 410/4885MAPT 888/4885SMN1; SMN2 484/4885
US-10639345-B2 Compositions for preserving photoreceptor cells, retinal pigment epithelial cells, or visual function ALDH1A2, PDE6B, PDE6A RIPK1 136/4885MAPT 1484/4885SMN1; SMN2 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.